Tag: NEOVACS
NEOVACS: Information relating to the total number of voting rights and shares making up the share capital – 04/10/2024 at 6:00 p.m.
Suresnes, April 10, 2024 – 6 p.m. CET – – Néovacs (Euronext Growth Paris: ALNEV), a biopharmaceutical company at a preclinical stage developing new therapies for inflammatory and autoimmune diseases,…
Neovacs: The nominal value of the share is reduced from 1 euro to 0.10 euro
HC Published on 04/03/2024 at 7:07 a.m. Photo credit © ChaunuPictures (Boursier.com) — Neovacs a…
NEOVACS: Néovacs confirms its qualification as an Innovative Company – 04/04/2024 at 08:00
Suresnes, April 4, 2024 – 8 a.m. CET – Néovacs (Euronext Growth Paris: ALNEV), a biopharmaceutical company at a preclinical stage developing new therapies for inflammatory and autoimmune diseases, announces…
NEOVACS: Adjustment of the nominal value – 04/02/2024 at 8:00 p.m.
Suresnes, April 2, 2024 – 8 p.m. CET – Néovacs (Euronext Growth Paris: ALNEV), a biopharmaceutical company at a preclinical stage developing new therapies for inflammatory and autoimmune diseases, announces…
Néovacs announces the entry into national phases of the patent on its mRNA vaccines for allergies
By Hector Chaunu Published on 02/14/2024 at 08:01 a.m. Photo credit © Neovacs (Boursier.com) — Neovacs a biopharmaceutical…
NEOVACS: Information relating to the total number of voting rights and shares making up the share capital – 01/02/2024 at 6:00 p.m.
Suresnes, January 2, 2024 – 6 p.m. CET – – Néovacs (Euronext Growth Paris: ALNEV), a biopharmaceutical company at a preclinical stage developing new therapies for inflammatory and autoimmune diseases,…
Neovacs multiplies the nominal value of its shares by 10,000
(AOF) – Neovacs announces that it has decided to implement a consolidation of the shares making up its share capital, at the rate of 1 new share against 10,000 old…
NEOVACS: Information relating to the total number of voting rights and shares making up the share capital – 12/19/2023 at 7:00 p.m.
Suresnes, December 19, 2023 – 7 p.m. CET – Néovacs (Euronext Growth Paris: ALNEV), a biopharmaceutical company at a preclinical stage developing new therapies for inflammatory and autoimmune diseases, presents…
NEOVACS: Fundraising of 0.5 million euros – 11/16/2023 at 6:30 p.m.
Suresnes, November 16, 2023 – 6:30 p.m. CET – Néovacs (Euronext Growth Paris: ALNEV) announces a fundraising of 0.5 million euros through the issuance of OCEANE-BSA, with a nominal value…
NEOVACS: Néovacs will present the latest results of its kinoid IgE vaccine candidate during two international meetings – 10/11/2023 at 08:00
November 10: at the Mastocytes and Basophils Club of the French Society of Immunology which is organizing its second meeting, within the Imagine Institute in Paris November 27: 6 e…
Néovacs presents the latest results on its vaccine candidates targeting allergies
By Hector Chaunu Published on 06/11/2023 at 08:02 a.m. Photo credit © Neovacs (Boursier.com) — Neovacs a biopharmaceutical…
Néovacs: Boosted on the stock market by the Pharnext file
(CercleFinance.com) – With gains of 33%, Néovacs shares topped the biggest gains on the Paris market on Monday, boosted by the prospect of a major contract for its subsidiary Pharnext.…